 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 1 of 48 
 
 
PROTOCOL TITLE : 
A single -center open -label study to determine the effect of diet on microbiome signatur es 
in Crohn's disease patients  
 
NCT [STUDY_ID_REMOVED]  
 
PRINCIPAL INVESTIGATOR:  
 [INVESTIGATOR_137620], Ph.D., R.D., L.D  
Department of Nutrition, School of Medicine  
Division of Gastroenterology and Liver Diseases, School of Medicine  
 Digestive Health Institute  
 Case Western Reserve University  
 [EMAIL_2825]  
 
UH  SITE  INVESTIGATOR:  
Fabio Cominelli, M.D., Ph.D.  
 Chief, Division of Gastroenterology, University Hospi[INVESTIGATOR_137621], Digestive Health Research Institute  
 Director, NIH Cleveland Digestive Diseases Research Core Center  
 Chief Scientific Officer, Digestive Health Institute , CWRU  
 [EMAIL_2826]  
 
UH FACULTY ADVISOR:  
 
OTHER DEPARTMENTS INVOLVED IN THIS STUDY (IF APPLICABLE) :     
Metabolomics Core, CWRU  
Genomics Core, CWRU  
UH Dhams  Clinical Research Unit, University Hospi[INVESTIGATOR_137622] (study foods)  
 
VERSION NUMBER:  
n/a  
 
DATE:  
 12/13/2022   (last updated)  
 
 
 
 
 
 
 
 
 
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 2 of 48 
Indicate t he origin of this protocol  (who conceived of and leads the development of the 
protocol regardless of funding) : 
‚òí  Investigator initiated  (Investigator(s) developed protocol, regardless of funding)  
‚òê  Industry  (Pharmaceutical, Device, etc.) (Industry developed protocol)  
‚òê  Federal  (NIH, DOD, etc.)  
‚òê  Cooperative Group  (SWOG, GOG, etc.)  
‚òê  Other  -  
 
Funding  
The proposed study is funded through the 2019 Pi[INVESTIGATOR_2268]/Feasibility Award (awardee Dr. A. Basson, 
principal investigator) under the Cleveland Digested Diseases Research Core supported by [CONTACT_137656]/NIDDK 1P30DK097948.  
 
As of October 2020, the proposed study is funded through the NIH/NIDDK K01 Research 
Award (1K01DK 12700801) awarded to AB, principal investigator.  
 
Time and resources for this research are supported by [CONTACT_137657]055812, DK091222 
and D K097948 (to FC, faculty mentor), T32 DK083251 and F32DK117585 (to AB, principal 
investigator), and 2P01DK091222 Germ -free and Gut Microbiome Core and R21DK118373 . In 
addition, this samples (stool) collected in this study will be used in experimental mouse s tudies 
supported by [CONTACT_137658], the Histology Imaging, and Tissue Biorepository Cores of the 
NIH P30 Silvio O. Conte Cleveland Digestive Diseases Research Core Center.  
Objectives   
Brief Summary:  
This protocol is designed to compare the effectiveness of a dietary intervention  for 7 day s, given 
to patients with Crohn's disease (CD) in remission:  a soy -based diet, which has  been 
demonstrated to have numerous health benefits. The protocol will also co mpare the effectiveness 
of the soy -based dietary intervention  vs. an identical diet without soy for 7 days , given to 
subjects with Crohn's disease (CD) and to controls subjects without a diagnosis of Crohn‚Äôs 
disease. The diet will be compared to participant ‚Äòbaseline‚Äô (pre -diet) in terms of its ability to 
change the composition of gut bacteria.   
 
Primary outcome measure  
1. Maintaining the quiescent disease status or prevent worsening of disease activity of the 
patient with Crohn‚Äôs disease (CD) after consuming the study diet .  
‚Ä¢ Symptomatic remission assessed daily, using the short Crohn‚Äôs Disease Activity 
Index1 (sCDA I), in combination with the Crohn‚Äôs Disease Activity Index2 (CDAI) 
and the Harvey Bradshaw Index3 (HBI).  Fecal MPO will also be assessed.  
Secondar y outcome measure  
1. Gut bacteria composition  
‚Ä¢ Gut bacteria composition measured by 16S rRNA gene amplicon sequencing,  
2. Gut bacteria metabolites  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 3 of 48 
 
Background  
Introduction  
This study will be conducted in full accordance with all applicable University Hospi[INVESTIGATOR_137623] (UHCMC)  Policies and Procedures and all applicable Federal and 
state laws and regulations.  This protocol is designed to determine the effect o f a short -term diet 
intervention  on gut bacteria composition and dietary -induced changes t o the metabolites the diet  
produce s. 
 
Background and Relevant Literature  
Crohn‚Äôs disease (CD), a subtype of inflammatory bowel disease (IBD), affects more than 
600,[ADDRESS_156431] one bowel resection over their disease course, with many patients requiring 
multiple resections.4, 5 The mos t feared complication of repeated bowel resections is short gut 
syndrome, a condition with results in chronic diarrhea, nutrient malabsorption, malnutrition and 
often requires long term artificial nutrition. Other complications of CD include mouth 
‚Äòextrain testinal‚Äô manifistations (complications outside of the intestines), affecting the eyes (e.g. 
uveitis and epi[INVESTIGATOR_227]), joints (arthritis and arthralgia), skin (erythema nodosum, pyoderma 
gangrenosum), or other organs (e.g. , kidney stones, blood clots).  
Despi[INVESTIGATOR_137624], including the integral role of gut bacteria in disease pathogenesis, the precise 
cause of the disease is still unknown, and available treatment modalities are not curative with the 
majority resulting in significant side effects.  Numerous medications are used in the treatment of 
CD, nearly all of which suppress the immune system (reviewed in 6, 7). The most effective of the 
currently available medications are antibodies directed against tumor necrosis factor Œ± (anti -
TNF) used in conjunction with a second immunos uppressant medication (either a thiopurine or 
methotrexate). However, available medical therapi[INVESTIGATOR_137625] a fraction of CD 
patients and, even with this approach remission rates are <60%[ADDRESS_156432] high rates of disability,15, 16 reduced quality of 
life, 17, 18, 19, 20 and reduced life expectancy rel ative to the general population.20 Concerns about 
these uncommon but life threatening adverse effects strongly influence patients‚Äô choice of 
medical therapi[INVESTIGATOR_014].21, [ADDRESS_156433] profile and acceptable methods of delivery.  
Diet is considered the main driving force in shapi[INVESTIGATOR_137626], in 
turn,  the metabolites  they produce . Today, gut microbiota modulation by [CONTACT_137659] a 
well-advocated strategy in the therapeutic management of Crohn‚Äôs disease (CD).  However, no 
specific recommendations exist for CD patients , and little is known regarding the microbiota -
mediated effects of diet on host immune systems, particularly for patients with evidence of 
residual active CD or in context to intra -individual varia bility in microbial profiles.23  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156434] antioxidant and cytoprotective effects in cultured human 
bowel cells. Furthermore, in mice induced with IBD administered a diet substituted with 12% 
soy protein concent rate had reduced weight loss and attenuated inflammation.  Many questions 
about the underlying mechanisms behind the anti -inflammatory effect remain, however soya -
oligosaccharides have been proposed to increase bacterial diversity as well as selectively en rich 
Bifidobacterium species, a known producer of butyrate in the gut.25, 26 However, evidence level 
is not enough to appreciate the potential efficacy of a plant -based diet in IBD.  
 
Inclusion and Exclusion Criteria  
Diet Intervention:  
 Inclusion  Criteria  
1. Age range: from 18 to 65  years  
2. Male or female  
3. Control subjects : no  documented diagnosis of CD. 
4. CD subjects: Documented diagnosis of Crohn‚Äôs disease  with a Harvey Bradshaw Index 
(HBI) score <4  (‚ÄòCD remission ‚Äô), or with HBI  score >8 (‚ÄòCD moderate disease ‚Äô) 
5. Capable of providing consent to participate  
[ADDRESS_156435] at screening visit in females of childbearing potential  
9 Able to take oral nutrition and medication intake for 3 months prior to and at time of 
study enrolment.  
10. ‚ÄòCD remission‚Äô subjects: No change in ‚ÄòIBD related‚Äô medications within [ADDRESS_156436] (pre -screening): 
biologics, immunosuppressants, corticosteroids.   
 
 Exclusion Criteria  
1. Short bowel syndrome.  
2. Hospi[INVESTIGATOR_9643]  
3. Body mass Index <19 kg/m or ‚â• 35. 
4. Known clinically significant liver/gallbladder/pancreatic disease/dysfunction  
5 Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively 
impaired participants, d ementia patients.  
6 Uncontrolled Diabetes Type I type II  
7 Known drug abuse.  
8 Known parasitic disease of the digestive system.  
9 symptomatic intestinal stricture.  
10 Presence of an ostomy.  
11 Known concurrent malignancy.  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 5 of 48 
12 Other conditions that would be a contraindication to and of the study di ets (e.g. Soy, 
peanut, wheat, gluten allergy.) or preclude the participant from completing the study  
13 Start of new ‚ÄòIBD related‚Äô medications within 8 weeks prior to enrollment: biologics, 
immunosuppressants, cortic osteroids.  
14 Documented C difficile colitis within four weeks of screening  
15 Well -founded doubt about the patient‚Äôs cooperation.  
[ADDRESS_156437] 30  days.  
20 History of <3 natural bowel movements per week.  
21 Unable to a ccess to technology that permits the daily completion of study related 
activities . 
22 Currently consuming a soy -based diet  
23  
 
Number of Research Participants  
For the diet intervention, w e will enroll 30 subjects per group  from  the UHCMC Digestive 
Health Institute . The enrollment total could increase to a maximum of 40 per arm,  if subjects 
agree to enroll in the study  for a second time to complete the other diet intervention.  
 
Vulnerable Populations  
‚Ä¢ Indicate specifically if you will include each of the following special populations by 
[CONTACT_61951] : 
‚òê  Adults unable to consent  
 ‚òê  Minors  (infants, children, teenagers)   
 ‚òê  Wards of the state  
  ‚òê  Foster Children  
 ‚òê  Pregnant Women   
 ‚òê  Neonates  
‚òê  Neonates  of Uncertain Viability  
 ‚òí  Employees of CWRU or UHHS  
 ‚òê  Prisoners  
 ‚òê  Illiterate Individuals  
 ‚òê  Non-English Speaking  
 ‚òí  University Students  
‚òê  None  
 
‚Ä¢ If excluding pregnant women, illiterate or non -English speaking individuals, provide 
a scientif ic rationale for the exclusion.  Inconvenience or cost is not an acceptable 
rationale . 
The study protocol involves a 12 -hour fasting period that precedes the soy based dietary 
intervention. Because of this, both pregnant woman and individuals with diabetes will be 
excluded. In addition, because the dietary intervention will involve specific written instructions 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 6 of 48 
to participants regarding the diet and respective 12 -hr fasting period, and because participants 
will be required to complete daily online surveys, illiterate individuals will be excluded.   
‚Ä¢ If the research involves individuals that ar e included in a vulnerable population, 
describe the additional safeguards included to protect the rights and welfare of the 
individuals  for each population indicated . 
Students, Employees of CWRU or UHHS will be included  because our study intends to inclu de 
individuals from heterogeneous demographics who attend the Digestive Health Institute at UHHS. In this 
study, the  safeguards  described in this protocol to protect the rights and welfare of  all potential study 
participants are adequate to protect the rights and welfare  of the special requested populations.  
 
  
Recruitment Methods   
3. Which of the following methods will be used to recruit research participants.  
‚òí  Email  
‚òí  Phone call 
‚òí  Letter  
‚òí  Advertisement  (e.g., poster, flyer, etc.)  
‚òê  Social media  
‚òê  Other.  Please specify : I will complete the UH Letter Recruitment Form . In addition, I 
intend to use the CRC referral lists from Redcap, ResearchMatch, and TriNetX.  
 
4. Describe when, where, and how potential research participants will be recruited.   
We will send a recruitment letter (UH Letter Recruitment Form) via mail to potential 
research participants. The source of addresses of potential subjects will be patients und er the care 
of [CONTACT_137720] and [CONTACT_137721] at the DHI  Ahuja and DHI University Hospi[INVESTIGATOR_137627] C enter  (UHCMC) . Control subjects ( individuals  without CD  diagnosis ) will be recruited 
in the same  manner, as well as via a flyer advertisem ent posted within the DHI outpatient waiting 
area, the Biomedical Reseach Building  (bulletin board located on each floor of the elevator area)  
CWRU , as well as the 6th floor of Bolwell by [CONTACT_137660] . In addition, we will use the 
CRC referral lists from Redcap, ResearchMatch, and TriNetX.  A prescreening survey in RedCap 
will be used to assist potential  healthy control  participant identification via ResearchMatch.  We 
will also advertise the study using the IRB -approved flyer in the Department of Nutrition, 
CWRU, newsletter. Potential  healthy  control subjects will also be recru ited from the following 1) 
Researchers affiliated with NIH National Institute Diabetes and Digestive and Kidney Diseases 
(NIDDK) Digestive Diseases Research Core Centers (DDRCC) Faciliti es, 2) Researchers 
registered with  the Taconics Biosciencs,  ‚ÄòGnotobiotics ‚Äô and American Association for 
Laboratory Science (AALAS) . 
We will send to a maximum of 1000 people  to hit our target enrollment of 60 for the diet 
intervention study .  We will stagger the sending of recruitment letters  each month, so that only  60 
go out at a time. Recruitment letters  and introductory survey emails  will be sent to all patients 
with scheduled appointments within the next 60 -90 days. Monitoring of opt out requests will be 
performed daily by [CONTACT_137661].  
Diet intervention recruitment letters: Participants who do not opt out will be contact[CONTACT_137662] 14  days by [CONTACT_137663] (Telephone script). The study coo rdinator 
will attempt to contact [CONTACT_137664] a total of 4 times. A voicemail will be left 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156438] will 
obtain consent, but not participant‚Äôs signature.  Subjects will be given the opportunity to ask 
questions and will be prov ided a copy of the Study Consent  Document by [CONTACT_137665]. Subjects will then be contact[CONTACT_137666] a screening visit (visit 1), and if study eligibility is 
confirmed, and informed consent provided, enrolled into the study.  
No data collection or other study procedures will take place until the potential participant 
provides written informed consent to participate in the research study. Phone contact w ill be used 
for determining interest in the study  (after recruitment letter sent) and scheduling of study visit 1  
(eligible participants identified by [CONTACT_137667]) by [CONTACT_9137].  
The informed consent, screening, enrollment and baseline data collection which make up 
visit [ADDRESS_156439] completed the study will be offered the option to enroll/participate 
in the study a second time, to receive the other  diet not originally assigned. Recruitement will 
occur via recruitm ent letter  and telephone contact.  For the latter, the  study coordinator will 
attempt to contact [CONTACT_137664] a total of 4 times (voicemail script attached). 
A voicemail will be left if there is no answer after the first attempt to contact [CONTACT_137668].  The study c oordinator will leave one additional follow -up voicemail.  
Participants may participate for a second time in the study at any point following completion of 
the study for the first time. Participation will in the study for a second time will require re -
conse nt.  Reconsent will occur in person at UHCMC.  
 
5. Describe the source (e.g., from what department, EMR, etc.) of the research participants.  
Subjects will be sourced from the gastroenterology outpatient clinic digestive 
health services of the Digestive Health Institute (DHI) located at University Hospi[INVESTIGATOR_137628] . Outpatient appointments are held at either site weekly at the 
DHI.  In addition, we will use the CRC referral lists from Redcap, ResearchMatch, and TriNetX.  
We will also advertise the study using the IRB -approved flyer in the Department of Nutrition, 
CWRU, newsletter. Potential healthy control subjects will also be recruit ed from the following 1) 
Researchers affiliated with NIH National Institute Diabetes and Digestive and Kidney Diseases 
(NIDDK) Digestive Diseases Research Core Centers (DDRCC) Facilities, 2) Researchers 
registered with  the Taconics Biosciencs,  ‚ÄòGnotobioti cs‚Äô and American Association for 
Laboratory Science (AALAS) . 
 
 
6. Describe the methods that will be used to identify  potential research participants . 
Potential research participants will be identified by [CONTACT_85842] s lists scheduled 
within 90 days and patients seen within previous 180 days with treating 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156440] potential participant 
identification via ResearchMatch.  We will also advertise  the study using the IRB -approved flyer 
in the Department of Nutrition, CWRU, newsletter. Potential  healthy  control subjects will also be 
recruited from the following 1) Researchers affiliated with NIH National Institute Diabetes and 
Digestive and Kidney Diseases (NIDDK) Digestive Diseases Research Core Centers (DDRCC) 
Facilities, 2) Researchers registered with  the Taconics Biosciencs,  ‚ÄòGnotobiotics ‚Äô and American 
Association for Laboratory Science (AALAS) . 
 
 
7. Describe the feasibility of recruiting the required number of suitable research participants  
within the agreed recruitment period. For example, how many po tential research 
participants do you have access to?   
The Digestive Disease Institute at Case Medical University Hospi[INVESTIGATOR_137629] a very large 
patient volume with more than 49,000 annual patient visits registered, of which include 
986 annual CD outpatient visits per year. The majority of CD outpatients are seen at the 
two flagship sites of the Digestive Health Institute (DHI), Case Medical Center (530 CD 
outpatients per year) and Ahuja Medical Center (260 CD outpatients per year), both free 
standing hospi[INVESTIGATOR_137630]. Participant screening and e nrollment will 
occur only at one site, UH Ahuja Medical Center . The Department of Gastroenterology 
has [ADDRESS_156441] or sees 40 outpatients 
per week, approximately 50% of which have CD. An estimated accrual rate of 1 eligible 
patient  per month generates a conservative s tudy accrual period of up to 12  months.  
 
Setting  
Physical location where i dentification and recruitme nt of all subjects , pre -screening, 
consent process, participant enrollment and all in -person visits will occur in a private 
patient room at the following site s: 
Digestive Health Institute (DHI)  
UH Physician offices  
[ADDRESS_156442]  
CMC Bolwell 6th floor  
Cleveland, Ohio, [ZIP_CODE]  
 
Dahms Clinical Research Unit (DCRU)  
[ADDRESS_156443]  
Lakeside Building, 6th floor  
Cleveland, Ohio, [ZIP_CODE]  
 
 
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 9 of 48 
Physical location where a ll receipt and processing of stool samples will be  conducted : 
Digestive Health Research Institute (DHRI)  
Division of Gastroenterology and Liver Diseases  
Case Western Reserve University  
Biomedical Research Building, 5th floor (Cominelli Laboratory)  
[ADDRESS_156444]  
Cleveland, OH, [ZIP_CODE] . 
 
Consent Process  
‚Ä¢ Indicate whether you will be obtaining consent : 
‚òí  Yes  ‚òê  No 
If yes, answer the following questions:  
‚Ä¢ Describe w here the consent process  will take place : 
The formal consent process will occur in a private patient room in the Digestive Health 
Institute (DHI) UHCMC , or at the Dahms Clinical Research Unit ( DCRU) at UHCMC . 
Study site visit location will be  based on patient preference . Reconsent will occur in 
person at the same locations.  
‚Ä¢ The time that will be devoted to the consent discussion:   
The informed consent, screening, enrollment  and baseline data collection which make up 
visit 1 can occur on the same day or be completed across several days.  
 
‚Ä¢ Any waiting period available  between informing the prospective subject and 
obtaining the consent :  
Participants will be permitted to provide informed consent at the time of the consent 
discussion during study visit 1 or they may to come back to provide written informed 
consent  if they choose to do so (would require a second scheduled study visit 1).  
 
‚Ä¢ Steps that will be taken to ensure the research participants‚Äô understanding:  
Potential participants will be given a copy of the consen t form and the investigator/ study 
coordinator will read the consent form with the participant and answer any questions. In 
addition, the potential participant will be given ample time to review, or return a different 
day. The study coordinator will ask th e potential participant to repeat or paraphrase 
understanding of different points of discussion, as well as ask open -ended questions or 
non-directive questions to ensure understanding.  
‚Ä¢ Any process to ensure ongoing consent :  
Informed consent will be obt ained from each subject at entry into the study. No 
study activities will occur until Informed Consent occurs. For the in-person consent ; the 
entire study, study procedures, and intervention will be explained to the participant as 
well as the risks involve d to the participant in participating. They will be made duly 
aware that participation in the research study is voluntary and they do not lose any of 
their rights by [CONTACT_114363]. If the participant would like to participate in the study, they 
will be ask ed to sign and date the consent form. The investigator obtaining consent will 
also sign and date the consent form and provide a copy to the participant. For potential 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156445] the potential 
participant then be  contact[CONTACT_137669] 1.  Participants 
who choose to participate in the study for a second time to receive the other diet not 
originally assigned , participation will require re -consent.  
 
 
‚Ä¢ The role of the individuals listed in the application as being involved in the 
consent process :  
The treating gastroenterologist will determine eligibility during the normally scheduled 
appointment of the patient  or at visit [ADDRESS_156446] will ask suitable patients whether they are interested in participating in 
the described dietary intervention study during the patient appointment. Subjects will be 
given the o pportunity to ask questions and will be provided a copy of the Study Consent 
Document  (to serve , in this case , as a Participant Information Document)  by [CONTACT_137665]. Subjects will then be contact[CONTACT_137670] a screening visit (visit 1) and if study eligibility is confirmed, and informed 
consent provided, enrolled into the study.  
 
 
‚Ä¢ Steps that will be taken to minimize the possibility of coercion or undue influence 
to the subjects:   
During the consent process, participants will be encouraged to ask questions. Ample 
time will be dedicated to answering all of the participants‚Äô questions to make sure 
they understand the study. They will be permitted to think about whether they want to 
participate, review the consent form on their own and discuss it with whomever they 
like and sign the consent form at a later visit. Potential participants will be reminded 
that the study is voluntary and they are not required to participate. Both the 
partic ipant and the person obtaining consent will sign the consent form. A copy of the 
consent will be provided to the participant.  
 
All participants will be given the opportunity to ask any questions to the study team 
and they will be provided with the contact  [CONTACT_137671] a research participant. All participants will 
be given time to read over the study information and discuss it with their doctor, 
family, or friends, if they would like.  
 
Participation is voluntary. Completion of online surveys (RedCap) and participation 
in other research studies is voluntary and not required for participation in the 
proposed open label diet intervention study. They can opt out of any questionnaire 
and ca n decline any research study. They can also withdraw at any time from the 
study.  
 
 
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 11 of 48 
‚Ä¢ Indicate if you will be asking for a w aiver or alteration of consent process or 
documentation (consent will not be obtained, written consent will not be 
documented)  
‚òí  Yes  ‚òê  No 
 
If yes, indicate which part of the consent process you are requesting to be waiver or 
altered  and the rationale for requesting the waiver or alteration.  
‚òí  I will o btain consent , but not participant‚Äôs signature  
‚òí  I will obtain  consent, but request a waiver for pre -screening purposes  
 ‚òê  I will obtain  consent, but request a waiver of some of the elements of consent  
                  (e.g. use of deception)  
 ‚òê  I will not obtain consent  and I am r equesting a full waiver of consent  
  
1. Give the rationale for the request of a waiver or alteration of the consent process or 
documentation :       
Clinical appointment schedules are available to all gastroenterologists each week 
for outpatient clinic visits and include patient name, appointment time and patient 
diagnosis (e.g., Crohn‚Äôs disease vs ulcerative colitis). The study coordinator will 
send r ecruitment letters and conduct follow up phone calls , as well as introductory 
emails for the online survey  to patients on behalf of their treating 
gastroenterologist . A waiver of the consent process for the study coordinator to 
manage sending of recruitme nt letters, opt out requests and providing follow up 
phone contact [CONTACT_137672].  
Written informed consent must still be obtained at the in person screening visit.  
No study procedures will occur until written consent is obtained. E-Consent 
consent must be obtained for the online survey.  
 
2. Explain how the research involves no more than minimal risk      
The PHI obtained includes patient name, address,  email address,  scheduled 
appointment time and diagnosis (e.g., Crohn‚Äôs disease vs ulcerative colitis). This 
information is available to the treating gastroenterologist the DHI. Identifiable 
information will not be used or disclosed by [CONTACT_137673].   
 
 
3. Explain why the waiver or alteration of consent will not adversely affect the rights and 
welfare of the participants :     
Identificatio n of potential participants via the treating gastroenterologist and use of 
recruitment letters with follow -up phone call (for those who do not opt out)  to 
determine interest in  participation, prior to the patient scheduled appointment is 
important to give subjects the opportunity to ask questions to the treating 
gastroenterologist at time of appointment. Written informed consent must still be 
obtained at the in person  screening visit. Prior to obtaining written consent, 
subjects will be given the opportunity to ask questions and will b e provided a copy 
of the Study Consent Document  (to serve, in this case, as a Participant Information 
Document)  by [CONTACT_137674].  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156447] of the 
participant to discuss the research (after sending recruitment letter) involving 
dietary intervention involves no more than minimal risk of harm to subjects and 
involves no procedures for which written consent is normally re quired o utside of 
the research context.  
5. If you will obtain consent, but not document consent in writing (e.g. over the phone, 
verbally, electronic survey, etc.), please describe and provide a rationale.   
     ‚òê  N/A  
 
Describe how you will be documenting that a research participant has consented :      
Following the recruitment letter, c ontacting the subject by [CONTACT_137675] a dietary intervention involves no more than minimal risk of harm to subjects and 
involves no procedures for which written consent is normally required outside of the research 
context.  Either before or at end of consent form discussion, participant will be provided with a 
copy of the Study Information Document. All informat ion, including the Subject Authorization 
for Release of PHI for Research (HIPAA Form) will be reviewed and all questions answered. 
Once the individual verbally agrees, the consent form will be signed and dated. The HIPAA 
authorization is in the consent for m.  A copy of the consent form with HIPAA Authorization for 
Release of PHI for Research will be provided to the participant.  The investigator will also keep a 
copy of: 1) the signed consent form with HIPAA authorization in the research medical records 
(stored in locked cabinet, DHI) and will be documented in the study data management system 
UH RedCap.  Documentation of when consent process took place and who consented will be 
recorded, and that consent form with HIPAA authorization and Study information do cument 
were given to participant.  
 
 
Additional Considerations for Consent Process with Adults    
Non-English Speakers   
 
‚òí  I am not enrolling non -English speaking individuals  in this research study . The following is 
justification for why non-English speaking individuals cannot be enrolled:   
Only English or non -native English speaking patients have been recorded to attend the outpatient 
services at the DHI.  
‚òê  I will be targeting non -English speaking adults  
‚Ä¢ Describe the process to ensure that the oral and written information provided to those 
research participants will be in that language during initial consent as well as 
throughout the study.   
 
‚Ä¢ List the language(s) other than English that will be targeted:    
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 13 of 48 
‚òê  I am not targeting non -English speaking individuals. If a non -English speaking individual is 
eligible for the trial, we will use the following procedures to enroll:   
‚Ä¢ Describe the process to ensure that the oral and written information provided to those 
research p articipants will be in that language during initial consent as well as throughout 
the study.   
 
‚Ä¢ List the language(s) other than English that will be targeted:  
 
Adults Unable to Consent  
‚òí  I am not enrolling adults unable to consent in this research study . 
 
 ‚òê  There is an anticipated direct benefit to the subject. Explain:   
 
 ‚òê  There is NOT an anticipated direct benefit to the subject. Explain:   
 
1. Describe the process to determine whether an individual is capable of consent.  
 
 
2. List the individuals from whom permission will be obtained in order of priority (e.g. 
durable power of attorney for health care, court appointed guardian for health care 
decisions, spouse, and adult child).   
 
 
3. For research conducted outside of the state, provide information that describes which  
individuals are authorized under applicable law to consent on behalf of a prospective 
subject to their participation in the procedure(s) involved in the research.  
‚òê  N/A   
 
4. Describe the process for assent of the research participants. Indicate:  
1. Which subjects  that are unable to consent will be required to give assent? If not all, 
explain why.   
 
2. Describe whether assent of the research participants will be documented and the process 
to document assent.   
 
 
‚òê The subject will be informed about the research to the extent compatible with the 
subject‚Äôs understanding . 
‚òê   Subjects  will be closely monitored . 
‚òê  The subject  will be withdrawn if they appear unduly distressed.  
 
Research Participants Who Are Not Yet Adults (infants, children, teenagers)  
‚òí  I am not enrolling participants who are not yet adults in this research study.   
 
1. Will parental permission be obtained from : 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 14 of 48 
‚òê  One parent even if the other parent is alive, known, competent, reasonably 
available, and shares legal responsibility for the care and custody of the child  
‚òê  Both parents unless one parent is deceased, unknown, incompetent, or not 
reasonably available, or when only one parent has legal responsibility for the 
care and custody of the child  
‚òê  Waiver of parental permission  
 
2. Describe whether permission will be obtained from individuals other than parents, and if 
so, who will be allowed to provide permission. Describe the process used to determine 
these individuals‚Äô authority to consent to each child‚Äôs participation in research .  
3. Indicate whether assent will be obtain ed from all, some, or none of the children. If ass ent 
will be obtained from some children, indicate which children will be required to assent .  
4. When assent of children is obtained , describe how it will be documented . 
5. For children who are pregnant, describe how assent and pe rmission are obtained . 
‚òê  N/A  
6. Describe how the risk is justified by [CONTACT_32117].  
7. Describe how the anticipated risk-to-benefit ratio  is at least as favorable to the subjects as 
that presented by [CONTACT_137676].  
 
Sharing of Results with Research Participants  
 ‚òí  Results will not be shared with research participants  
 ‚òí  Results will not be shared with research participants‚Äô doctors  
 
Study Design  
General Design  
DIET INTERVENTION  
This is an open label , single -center  study to compare the ability of a soy - based diet for 7 day s to 
change the  composition of gut bacteria (stool samples) in adult Crohn‚Äôs disease patients  and 
control subjects without a diagnosis of Crohn‚Äôs disease . Participants will be pre -screened by [CONTACT_137677] 1 at the Di gestive Health Institute (DHI) UHCMC , or at the Dahms Clinical Research 
Unit at UHCMC . The treating gastroenterologist will ask suitable patients whether they are 
interested in participating in the described dietary intervention study during the patient 
appointment.  Control subjects will be recruited in the same manner, as well as via a flyer 
advertiseme nt posted /available to patients  within the DHI outpatient waiting area , the Biomedical 
Reseach Building CWRU, as well as the 6th floor of Bolwell by [CONTACT_137660] . The 
gastroenterologist will obtain consent, but not participant‚Äôs signature .  Subjects will be given the 
opportunity to ask questions and will be provided a copy of the Study Consent Document (to 
serve, in this case, as a Participant Information Document) by [CONTACT_137678]. 
Subjects will then be contact[CONTACT_137679] c oordinator to schedule a screening visit (visit 1) 
and if study eligibility is confirmed, and informed consent provided, enrolled into the study. 
Participants will follow  either a soy -based diet  or identical  diet without soy to which they were 
randomized for 7 day s. A block randomization approach27 using pre -determined group 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 15 of 48 
assignments will be used every 2 healthy controls and every 2 CD subjects , the latter based on 
baseline HBI score (2 levels; score between 0 -4 ‚Äòlow‚Äô vs. 8-16 ‚Äòmoderate‚Äô) as this covariate has 
the potential to influence disease activity .  Randomization will occur after eligibility is confirmed 
AND the baseline stool sample is received; the participants assigned diet will be documented in  
REDCap .  The diets will be preceded by a [ADDRESS_156448] 2 fresh stool samples, each  collected  before and after diet 
intervention . Two blood draws will be taken (visit 1, end of study visit ; within 24hrs of completing 
diet) to calculate the CDAI and to measure C -reactive protein ( CRP) to be used as a third biomarker 
to complement fecal calprotectin and myeloperoxidase activity (MPO) measured in stool samples. . 
Participants will complete questionnaires each day for the entire duration of the study on well -
being (sCDAI;) , as well as a diet satisfaction questionnaire (end of each dietary intervention) and 
a diet history questionnaire. A dietary recall will be conducted in -person at visit 1 and 
telephonically (at time of stool collection) at baseline . One month after the  end of study visit, 
subjects will be sent a questionnaire asking about dietary choices (i.e. when study foods not 
provid ed). Changes to the composition of gut bacteria and differences in butyrate production will 
be analyzed in batch at the end of the study.   
 
Partic ipants will receive all of study  meals and snacks at no cost shipped directly from the food 
vendor to the par ticipant.  Participants will receive one food deliver y.   To improve feasibility of 
stool sample collection, a medical courier same day service will be available at no cost to the 
participants.  
Participants who have completed the study will be offered the option to participate  in the study 
for a seco nd time, to receive the other diet not originally assigned. Recruitement letters sent via 
mail and telephone contact [INVESTIGATOR_31235]. Participation for a second time may occur at any point 
following completion of the study for the first time. Participation will require re -consent.  All 
study procedures , as originally described in the protocol , remain unchanged.   
 
Study Procedures  
2. STUDY PROCEDURES  
2.1.2 DIET INTERVENTION:  
The informed consent, screening, and baseline data collection which make up visit 1 can occur 
on the same day or be completed across several days.  A phone call reminder will be placed by 
[CONTACT_137680] [INVESTIGATOR_137631] o f each study phase and/or for 
upcoming food deliver y. 
[IP_ADDRESS] Randomization.   A block randomization approach27 using pre -determined group 
assignments will be used every 2 healthy controls, and every 2 CD subjects , the latter  based on 
baseline HBI score (2 levels; score between 0 -4 ‚Äòlow‚Äô vs. 8 -16 ‚Äòmoderate‚Äô) as this covariate has 
the potential to influence disease activity.  Randomization will occur after eligibility is confirmed 
AND the baseline stool sample is received;  the participants assigned diet will be documented in  
REDCap.  If participants choose to participate in the study for a second time, no randomizati on 
will occur as the participant will receive the other diet, originally not assigned.  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156449] the following:  
‚Ä¢ Informed Consent (if not done so already)  
‚Ä¢ Medical History  
‚Ä¢ Urine Pregnancy  
‚Ä¢ Diet History Questionnaire; DHQ  
‚Ä¢ 24-hour dietary recall  
‚Ä¢ Medications, supplements/vitamins  
‚Ä¢ Vitals   
‚Ä¢ Height and weight (calculation of BMI)  
‚Ä¢ Short Crohn‚Äôs Disease Activity Index (sCDAI)  
‚Ä¢ Blood draw for hematocrit (calculate CDAI)  and C -reactive protein (CRP)  
‚Ä¢ Stool Colle ction  
‚Ä¢ Provide study instructions and stool collection kits  
 
2.[ADDRESS_156450] has been 
created and tested (see data collection instrument details).  
2.2.[ADDRESS_156451].  Diet recall will 
involve asking/quantifying the participant what they ate the day before. A registered dietitian  
from the CTSC Bionutrition  will complete this.  
2.2.3 Diet History Questionnaire (DHQ III):  
The par ticipant will complete a  DHQ via the web -based system (https://www.dhq3.org ) 
constructed by [CONTACT_59743][INVESTIGATOR_137632], Division of Cancer Control 
and Population Sciences National Cancer Institute (NCI). The research tool is developed as a 
computerized tool and the database is intended for researcher s to develop study projects that 
allow assignment of unique alphanumeric username [CONTACT_137718] a study project 
developed by a researcher  allowing absence of identifying information in data collection.  
Participants will complete the online DHQ at home immediately following the screening visit 1. 
Alternatively, the participant may complete it at their visit if a computer with internet is 
available. It will t ake approximately 30 minutes to complete. The investigator will assign the 
participant their unique userID and passcode where they will be able to login and access the 
questionnaire.  
2.2.4 sCDAI  
Patient symptoms will be monitored using the sCDAI1 over the durati on of the study. A 
minimum of 5 and maximum of 7 days of patient reported symptoms will be required to compute 
the sCDAI during study diet to compare to baseline CDAI and HBI. (Note: symptoms are 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 17 of 48 
assessed/calculated for the previous day) . The participant w ill accomplish this via daily online 
surveys (RedCap) sent via email to the participant after informed consent is obtained at visit 1. 
The sCDAI is computed using the following equation where L is the number of liquid or very 
soft stools, A is the rating of abdominal pain (0 -3, none to severe), W is the rating of general 
wellbeing (0 -4, generally well to terrible), n is the day of follow -up, and d is the number of days 
of data used to compute th e sCDAI.  
ùë†ùê∂ùê∑ùê¥ùêº=44+7
ùëë‚àó((2‚àó‚àëùêøùëë
ùëõ=1)+(5‚àó‚àëùê¥ùëë
ùëõ=1)+(7‚àó‚àëùëäùëë
ùëõ=1)) 
2.2.[ADDRESS_156452] be provided by [CONTACT_78772] 14 days prior to receiving the 
study food  (Phase II). Alternatively, participants can also provide a stool sample to visit 1. Fecal 
collection kits will be provided at visit 1; kits provided wil l be pre -labelled with participant 
unique study code ID. A medical courier service will be available for home pi[INVESTIGATOR_137633]. Stool samples will be received and signed for by [CONTACT_458] [INVESTIGATOR_137634], 5th Floor. 
The principal investigator [INVESTIGATOR_137635] 3 aliquots measure: i) to 
measure fecal calprotectin  and fecal myeloperoxidase activity , ii) batch analysis for mass 
spect rometry analysis, and iii) batch analysis for 16S rRNA gene sequencing. After receipt of the 
baseline stool sample study food items (Phase II) and stool collection kits will be shipped to 
participants .  
If a participant is unable to have a bowel movement over the 7 day period of the diet, the study 
coordinator can approve an extension of the period  until a bowel movement occurs (up to 7 
days).  After a [ADDRESS_156453] udy. 
 
2.3.2 Blood draw:  
One to two tubes of blood will be drawn by a DHI research nurse to determine hematocrit 
(calculate CDAI)  and for measurement of C -reactive protein (CRP). CRP levels will serve as a 
third biomarker to supplement the fecal calprotect in and myeloperoxidase activity measured in 
stool. An additional blood tube may be drawn. Blood tubes labelled with the participant unique 
study identifier, and other collection materials will be provided. After blood is drawn, the tube 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 18 of 48 
will be sent to the UH Laboratory services for determination of hematocrit and CRP levels. The 
additional tube will be spun and plasma extracted. Extracted plasma will be placed in a separate 
sterile tube, labelled with the participant unique study identif ier code and stored in a secure 
locked -80C freezer in the BRB 5th floor.  
2.3.3 Urine:  
Female participants of childbearing age will be asked t o take a urine pregnancy test.  
3. STUDY INTERVENTION  
Participants will follow  either a soy -based diet or identical diet  without soy  to which they were 
randomized for [ADDRESS_156454] diet stool sample. A phone call 
reminder will be placed by [CONTACT_137680] [INVESTIGATOR_137636]/or for upcoming food deliver y. 
Participants will re ceive daily online surveys sent from  UH RedCap server via email to complete 
during the study diet . Dietary  adherence will be evaluated by a food log as described above.  
Participants must collect a minimum of one stool sample any time between day 5 -7 durin g study 
diet (see below).  A satisfaction survey about the study diet will also be sent via email (UH 
RedCap) following completion of each diet.  
1.1 Study Intervention Protocol  
A phone call reminder will be placed by [CONTACT_137680] [INVESTIGATOR_137637]/or for the upcoming food delivery . 
 
Phase I: baseline ‚Äòpre -diet‚Äô study period  
‚Ä¢ Participants continue to consume their usual foods.  
‚Ä¢ Completion of DHQ (if participant did not complete at visit 1)  
‚Ä¢ Dietary Recall ‚Äì telephone contact [CONTACT_46144] (Dhams Bionutrition)  
‚Ä¢ complete sCDAI  
‚Ä¢ Stool collection:  participants must collect one stool sample A medical courier service will 
be available for home pi[INVESTIGATOR_137638] . Once stool sample is received 
participant is eligible to receive study diet.   
‚Ä¢ Signed d elivery of study food items  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 19 of 48 
‚Ä¢ Ensure end of st udy visit is schedul ed 
 
Phase II: Twelve -hour overnight fast (8:00pm -8:00am)  
‚Ä¢ A [ADDRESS_156455] meal no later than 8:00pm the evening prior to commencement of their 
study  diet. Plain water will be permitted.  
‚Ä¢ Stool collection  (optional) : participants may collect one stool sample in the morni ng at 
the end of the [ADDRESS_156456] (prior to starting the diet, see below). A medical courier service 
will be available for home pi[INVESTIGATOR_137639] I-diet: Soy -based diet intervention ( 7 day s):  
The assigned study  diet will commence in the morning following the [ADDRESS_156457] (see 
Phase II), and will continue for 7 consecutive days. The diet will be based on the detailed 
descriptions according to the American Heart Association, US Food and Drug Administration 
(FDA), and the Soyfoods Association of North America Website, which all promote soy 
products as having beneficial nutrient pr ofiles with a daily consumption of 25 grams or more of 
soy prote in (average serving = 6.25 grams), upper limit of 50g. Carbohydrates will be restricted 
to simple carbohydrates. The only carbohydrates that will be included in meals will be 
monosaccharides: glucose, fructose, and galactose. No grains will be included in the soy -based 
diet. Saccharin and honey will be included in addition to moderate use of sorbitol and xylitol. 
Canned fruits and vegetables will be included. Soymilk will be included in the die t without 
limitation. Animal based food products, eggs, dairy (yogurt, cheeses, milk etc.), fish, 
unprocessed meats, processed, canned, and smoked meats will not be included or permitted 
during the diet intervention.  
 
‚Ä¢ sCDAI questionnaire    
‚Ä¢ Stool collection: participants must collect at least one stool sample. Sample collection 
should occur any time between days 5 -7 on study diet. A medical courier service will be 
available for home pi[INVESTIGATOR_137640]: On line diet 
satisfac tion/adverse e vents questionnaire  
 
 
Phase IV: End of Study Visit and Resume usual eating habits (minimum of 7 day s) 
Following the completion of the 7 day  plant -based diet the participant will be instructed to 
resume their usual eating habits.  
‚Ä¢ Attend end of study visit within 24 hours of diet completion.  
‚Ä¢ Online diet satisfaction questionnaire  
‚Ä¢ sCDAI  
 
 
End of Study visit  
The end of study visit will take place following no more than [ADDRESS_156458] for end of study HBI score  (CD 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 20 of 48 
patients only) . As a secondary clinical outcome, we will measure the CDAI.  The CDAI includes 
measurement of hematocrit with 5  days of patient symptoms (sCDAI). Blood sample will be 
drawn by [CONTACT_137681] (calculate 
CDAI). Participants will be asked to complete a 24 -hour dietary recall, and provide information 
about adverse  events, medications, supplement use.  Participants will also be weighed.  
The following will be conducted at the end of study visit:  
 
‚Ä¢ Blood draw  
‚Ä¢ Stool collection  
‚Ä¢ Weight  
‚Ä¢ Instructions to resume usual eating habits  
‚Ä¢ Adverse Events  
‚Ä¢ Physical exam by [CONTACT_137682]  (CD patients only).  
 
Blood draw:  One tube of blood will be drawn by a DHI research nurse to determine 
hematocrit (calculate CDAI). An additional blood tube will be drawn for evaluation of 
plasma metabolites. Blood tubes labelled with the  participant unique study identifier, and 
other collection materials will be provided. After blood is drawn, the tube will be sent to the 
Core Laboratory services at CWRU for determination of hematocrit levels. The second tube 
will be processed in the same  manner as in Visit 1.  
 
End of Study Follow Up Survey (1 and 6 months after end of study visit)  
1. Complete online Diet History Questionnaire (DHQ)  
2. Follow up diet questionnaire  
 
3.2 Intervention Regime  
Participants will be provided with fully prepared meals , including beverages and snacks  from 
CTSC Research Bionutrition (Dhams, Rainbow Babies, University Hospi[INVESTIGATOR_600]) totaling a 
minimum of [ADDRESS_156459] to eat all of the food provided.   Participants 
will receive these meals for both of the diet (soy, plant) interventions. Some of the meals will 
require heating. Some of the beverages will require the addition of water for reconstitution. Plain 
water will be allowed  ad libidum.  Participant s will be provided with detailed instructions and 
recipes for preparing their food.  If participants require additional food to that provided (i.e. the 
2500 kcal) additional food delivery will be provided at no cost to the participant.  
3.2.1 Receipt of Food  & Storage  
Participants will receive two shipments of food to their home (or another location, if desired)  for 
the diet intervention (i.e. 2 shipments total for study period) ; one shipment prior to the start of 
the diet intervention  providing 3 days‚Äô worth of study meals, and a second shipment on day 3 of 
the diet intervention, providing the remaining study meals for that diet.  Alternatively, 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156460], lunch, dinner an d two snacks  and additional food items  for each day of the diet 
intervention.  F ood items/meals will be delivered fresh or frozen as appropriate  with sufficient 
ice packs to remain unrefrigerated until later that evening. Each ship ment will contain 
instructions on how to reheat the meal (if needed), whether or not the meal can be frozen and 
how long the meal can be kept under refrigeration before consumed.  Proper preparation with 
regard to reheating will also be included on a label  on each meal/snack. Each meal or snack will 
be labeled with the storage requirements for that meal (freeze, refrigerate, keep at room 
temperature). Additionally, each shipment will contain contact [CONTACT_137683]. The representatives can be contact[CONTACT_137684], its ingredients, preparation instructions etc.  
3.2.2 Preparation, Packaging & Delivery  
 All of  the study meals including snacks for this study will be prepared by [CONTACT_137685] a 
single kitchen.  All participants will receive their meals from CTSC bionutriton directly to their 
homes (or another location, if desired) via tracked courier. Food will arrive in a cooler box / 
cardboard box with the food inside surrounded by [CONTACT_137686]. The box will have a label 
reading ‚ÄúPerishable.‚Äù CTSC bionutriton will provide a report detailing all of the food deliveries 
including the date and time they were delivered and to whom; an adult must be present to sign 
for the delivery. Participants will return the empty food delivery coolbox at the end of study visit.  
3.2.[ADDRESS_156461] will precede  the assigned diet intervention. Participants will be instructed to not to 
eat or drink anything (except plain water) during the 12 hours prior to starting the diet. No juice, 
tea, coffee, diet soda or other beverage will be allowed. Participants will continue to take 
prescription medicat ions unless physician informs them otherwise. No exercise will be permitted 
during the fasting period. For convenience, participants will be instructed to stop eating and 
drinking after 8:00pm and to start eating the proposed diet no later than 8:00am the following 
morning.   
 
3.2.4 Resume ususal eating habits  
Following the completion of the  study diet the participant will be instructed to resume their 
usual eating habits (i.e. prior to study).  
 
4. STUDY EVALUATIONS AND MEASUREMENTS  
4.1 Study Evaluations  
4.1.1 Medical History  
The following information may be obtained from a combination of the participant‚Äôs medical 
charts by [CONTACT_137687]/or self -report:  
‚Ä¢ Medical and surgical history  
‚Ä¢ Crohn‚Äôs disease history  
‚Ä¢ Medication use  
‚Ä¢ Smoking  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 22 of 48 
‚Ä¢ Hospit alizations  
‚Ä¢ Laboratory test results ‚Äì albumin, C. difficile colitis, vitamin D, B -vitamin panel  
4.1.2 Demographic Information  
Gender, date of birth, race, email address will be collected from each participant. Medication and 
over-the-counter supplement and vitamin use will be collected at each visit.   A suitable address 
of the participant address (e.g., home or work) will be required for scheduled delivery of study 
food items.  
4.1.3 Current Symptoms  
Participants‚Äô current symptoms, both Crohn‚Äôs disease -related and otherwise, will be collected by 
[CONTACT_137688].  Crohn‚Äôs symptoms will also be collected through 
daily online surveys .  
4.1.4 Concomitant Medication  
Medication use and over -the-counter supplements, herbal and vitamin use will be collected at 
each visit.  
4.2 Study Measurements  
4.2.1 Vitals  
Participants will be weighed on a scale in the D igestive Health Institute clinic or Dahms Clinical 
Research Unit at each study visit. Participant‚Äôs height will be measured at Visit 1 using a 
stadiometer. Participants‚Äô seated blood pressure will be measured at Visit 1 and at the end of 
study visit.  
4.2.2 Laboratory Evaluations  
Fecal Calprotectin (FCP)  and fecal myeloperoxidase activity (MPO)  ‚Äì These biomarker s are a 
strong predictor of an outcome of importance to patients, the duration that they will remain free 
of symptoms of CD. It has been repeatedly demonstrated that patients with IBD who have an 
elevated FCP concentration have earlier relapse of disease. In addition, fecal MPO can change 
rapi[INVESTIGATOR_137641]. We will use th ese biomarker s as a surrogate for long -term 
disease remission s tatus (in conjunction with the HBI and sCDAI) in patients FCP assays will be 
completed by [CONTACT_458] (Human stool ELISA kit) at baseline and end of study. C-
reactive protein ( CRP) to be used as a third biomarker  to complement fecal calprotectin and 
myeloperoxidase activity measured in stool samples . 
All samples will be de -identified and tracked using study ID codes not derived from participants‚Äô 
personal identifiers.  
 
4.2.3 Plasma Collection  
One to two tubes (4 tsp) of blood will be drawn and centrifuged at visit 1 and at end of study 
visit for plasma separation and collection.  The plasma samples will be banked stored long -term 
for future research use related to this study. Possible use of the plasma samples include testing 
for serol ogical markers or other relevant metabolites.  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156462] resumed their usual eating habits.  
 
A simply designed plastic container called Fisherbrand ‚Ñ¢ Commode Specimen Collection 
System has been extensively used in Human Microbiome Project and will be used in this study. 
This collection system includes a plastic frame to fit the container securely under the toilet to 
avoid contamination by [CONTACT_137689]. Based on similar concept, a DIY stool collection 
option will be shown to participants in the event that their Commode is not available.  In the 
condition of 4 ¬∞C preservation, the allowable same day courier shipment time from participant to 
laboratory staff handling can be <24hr without significant microbial composition alteration . 
 
4.3 Medical Courier Service  
A 24hour, 7 -week day medical courier service for collection (e.g., home or work) of stool 
samples will be available to participants via s ame day telephone scheduling/request. This study 
will use American Expediting¬Æ, a medical courier service that meets all regulatory requirements. 
Drivers utilize medical transport bags that meet OSHA and US DOT 49CFR 173.[ADDRESS_156463] spi[INVESTIGATOR_137642] (HAZMAT) and biohazard specialists. The service 
ensures that a HIPAA secure chain -of-custody procedure is followed and that patient 
confidentiality is protected at all times.  In addition, the service will maintain samples specimen 
temperatures and carries dry ice at all times. The service (courier transport of diagnostic and 
infectious medical specimens, blood products, on site specimen pack and shippi[INVESTIGATOR_137643] 
24hr pi[INVESTIGATOR_9696] -up and delivery service) is available 24/7 for 365 days a year. Service delivery time 
range from: Express (1 hour), Rush (1.5 hours), Regular (2.5 hours), Standard (3.5 hours), STAT 
Medical (priority delivery time).   
 
All stool kits will be pre -labelled with participant unique study ID code not derived from 
participants‚Äô personal identifiers.  
 
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 24 of 48 
4.4 Stool sample preparation and processing  
Upon delivery of the stool sample by [CONTACT_137690], the 
investigator will process the sample. All samples will be processed anaerobically, separated into 
3 aliquots, to measure: i) fecal calprotectin  and fecal MPO , ii) stored at -80C, then sent in batch 
to Metabolomics Core, CWRU for evaluation and quantification of metabolites (short chain fatty 
acids, i.e. butyrate) using LC -MS or GC -MS methodologies,  and iii) storage at -80C until batch 
extraction  of fecal genomic DNA using QIAmp DNA mini Kit and analysed  in batch for 16s 
rRNA gene sequencing of the V3 -V4 region bacterial DNA using Illumina pro tocols by [CONTACT_137691], CWRU.  The remaining stool will be stored in sterile 15ml conicle tubes as 6g 
feces + (12mL phosphate buffer solution + (7% dimethyl sulfoxide)). Samples from this study 
will be stored and banked for future research use related to this study . 
 
All samples will be de -identified and tracked using study ID codes not derived from partic ipants‚Äô 
personal identifiers.  
 
4.5 Blood Sample preparation and processing  
One to two tubes of blood will be collected at visit 1 and at end of study visit (calculate CDAI). 
Hematocrit and C -Reactive protein levels will be measured at enrollment and at en d of study 
visit. In all cases, tubes will be centrifuged  and plasma will be aliquoted and frozen within one 
hour of collection in a locked -80¬∞C freezer dedicated to Biorepository samples in the Cominelli 
laboratory located on the 5th floor of the BRB, CWRU. Samples will be analyzed in batch  by 
[CONTACT_137692].  
 
All samples will be de -identified and tracked using study ID codes not derived from participants‚Äô 
personal identifiers.  
 
4.[ADDRESS_156464] eaten on the 
previous day.  In addition, a dietary recall will be performed telephonically at baseline . 
Diet History Questionna ire (DHQ)  will be completed confidentially, online by [CONTACT_137693] 1.  Alternatively participants may be able to complete the 
questionnair e at the DHI clinic during visit 1 if a computer with internet access is available.  We 
will use the National Cancer Institute‚Äôs DHQ III questionnaire that asks about food eaten in the 
past [ADDRESS_156465]. The DHQ will be used to determine differences 
in eating habits between participants.  Using a secure UH server, the study coordinatory  will 
download the Excel file containing study partici pants‚Äô questionnaire responses from a secure 
https website. https://www.dhq3.org   
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 25 of 48 
Study diet satisfaction surveys  will be administered via a UH RedCap survey following the study 
diet. T his will be a brief survey that will allow for free text comments from participants about 
their satisfaction and overall experience with the assigned diet.  
4.7.2 Symptoms  
We will assess symptomatic remission using the sCDAI survey administered via daily RedCap 
survey sent via email.  
4.7.3 Harvey Bradshaw Index (HBI):  
The HBI3 is a valid tool for assessment of disease activity in Crohn‚Äôs disease. The HBI consists 
of only of clinical parameters, with the first three items scored for the previous day. The HBI is 
compute d to include; general well -being (0 -4), abdominal pain (0 -3), number of liquid stools per 
day, abdominal mass (required physical exam ; pre-screening, end of study ), and complications 
(e.g., arthralgia). Patients who score 4 or less on the HBI are very lik ely to be in remission 
according to the Crohn‚Äôs Disease Activity Index. Patients with a score of [ADDRESS_156466], the 
HBI will be used in this study to identify suitable participants (i.e. CD patients in remission  vs 
active disease ). An abbreviated format (excludes abdominal mass evaluation) will be used for 
evaluatio n (online) of patient symptoms.  
4.7.4 Crohn‚Äôs Disease Activity Index (CDAI)  
As a secondary clinical outcome, we will measure the CDAI at end of study visit.  Computation 
of the CDAI is the sum of the following components over the course of 7 days (sCDAI) and 
multiplied by [CONTACT_137694]:  
Variable  Weighting factor  
Number of liquid or soft  each day for seven days  x 2 
Abdominal (graded from 0 -3 on severity) each day for seven days  x 5 
General well -being, subjectively assessed from 0 (well) to 4 (terrible) 
each day for seven days  x 7 
Presence of complications* x 20 
Taking Lomotil or opi[INVESTIGATOR_22032]  x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as 
definite)  x [ADDRESS_156467] weight^  x 1 
 
* One point each is added for each set of complications:  
‚Ä¢ the presence of joint pains (arthralgia) or frank arthritis  
‚Ä¢ inflammation of the iris or uveitis  
‚Ä¢ presence of erythema nodosum, pyoderma gang renosum, or aphthous ulcers  
‚Ä¢ anal fissures, fistulae or abscesses  
‚Ä¢ other fistulae  
‚Ä¢ fever during the previous week.  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156468] weight is derived from the patients  sex and height. CDAI remission will be defined as a 
CDAI<150 in the absence of the need for increasing corticosteroid dose or initiation of new 
therapi[INVESTIGATOR_137644]  
 
4.7.5 Comb ined CDAI, HBI and MPO  outcome  
As a primary outcome en dpoint, we will use sCDAI, CDAI and  MPO  to assess overall 
maintenance of symptomatic remission.  
[see study time line on next page]   
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 27 of 48 
 
Study Timeline  
 
 
 
 
Radiation and Radioactive Substances  
‚Ä¢ Does the research involve the use of radiation or radioactive substances ? 
 ‚òê  Yes     ‚òí  No  
   
 
ClinicalTrials.gov Information  
The study protocol has been registered in ClinicalTrials.gov under NCT number : [STUDY_ID_REMOVED]  
 
  
 
 Normally 
scheduled 
appointment  
 (Pre-Screen)*  Visit 1  
 Baseline (pre -
diet) 
Study  Diet 
End of Study 
Visit  
1 month and 6 
months after 
end of study  
Estimated time 
requirement of visit  30min*  90-
180min 30min  7-
days 120-
180min 10-min 
Finger Prick (blood 
glucose)   X     
Pregnancy Testing   X     
Vitals   X     
Height   X     
Weight   X     
Online Diet History 
Questionnaire (DHQ)    X   X 
Usual eating habits    x  x  
Harvey Bradshaw 
Index (HBI)  X    X  
Crohn‚Äôs Disease 
Activity Index 
(CDAI)   X   X  
Dietary Recall   X X    
Blood Draw 
(Hemoglobin)   X   X  
Demographics & 
Medical History   X     
Medication History   X   X  
Online sCDAI (daily)    X X   
Stool Collection    X X   
Diet Satisfaction 
Survey     X   
Adverse Events      X  
Follow up diet 
questionnaire       X 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156469] of Data to be Collected  
Note: If using REDCap , all selected identifiers below must be indicated as PHI . 
1. Indicate what identifiers you will collect  
‚òí  Name  
‚òí  Address  (e.g., Zip code, other geographical designation , etc. ) 
‚òí  Dates related to an individual  (e.g.,  Date of admission, birth, surgery, etc.)  
‚òí  Telephone number  
‚òê  Fax number  
‚òí  Email address  
‚òê  Social security number  
‚òí  Medical record number  
‚òê  Health plan beneficiary number  
‚òê  Account number  
‚òê  Certificate/license number  
‚òê  Any vehicle or other device serial  
‚òê  Device identifiers or serial numbers  
‚òê  Web URL  
‚òê  Internet protocol (IP) address  
‚òê  Finger or voice prints  
‚òê  Photographic images  
‚òê Other :  
 
2. List all other data to be collected for the research study (e.g. laboratory values, physician 
notes, length of stay, etc.)   
Other d ata to be collected in this study include:  Laboratory values, physician notes, 
medication history, demographic information (gender, ethnicity, marital status, place of 
birth, employment), diet history, smoking history, alcohol use, s tool & blood specimens, 
vitals.  
 
Perceptons ‚Äô on the role of diet and food safety on digestive symptoms , as well as 
individuals perceived willingness to change dietary practices .  
 
  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156470] in principle; recruitment, provision of diet and a daily survey ( sCDAI) form 
to complete online at home for 7 days, a fecal sample on day 1, and a fecal sample on day 7. The primary 
analysis will compare the absolute difference (before/after) using the paired t -test (or the non -parametric 
test) for ANOVA. Only patients that contribute to the two fecal samples before and after diet will be used 
for analysis. Attention will be placed on examining the reasons if patients drop out and do not complete 
the diet for both groups to ensure the cause of drop out is not due to diet  (chi-square stats and interviews 
to assess ‚Äòsafety of diet‚Äô). Continuous outcome measures, such as sCDAI, will compare before/after 
values using the Wilcoxon sign rank test (nonparametric paired test) and categorical variables using the 
chi-squared test. These analyses will be conducted separately for each treatment group. The identification 
of potential biomarkers will be examined using multivariable multinomial logistic (‚Äòno effect‚Äô, ‚Äòmoderate 
effect‚Äô, ‚Äòprominent effect‚Äô), linear, and linear mixed random  effect models (% of reduction in primary 
outcomes, e.g., CDAI, with and without controlling for clustered and repeated measures data) as it has 
been published recently by [CONTACT_978] [INVESTIGATOR_1238]/or the mentors.28, 29, 30, 31, 32, [ADDRESS_156471] potential health benefits, no interim safety is indicated. However, analyses will be 
conducted to monitor efficacy/study power (see section above) and data quality.  
 
Baseline Data  
We will utilize descriptive statistics to define the characteristics of the study participants. Continuous 
variables will be described as medians and interquartile rang es. Categorical variables will be defined as 
proportions. Formal statistical comparisons of these descriptive variables will be performed comparing 
the pre -(baseline) and post study diet data using the Wilcoxon rank sum test for continuous variables and 
the chi squared or Fisher‚Äôs exact test for categorical variables. Analysis will be performed using SAS, 
STATA, GraphPad and R. All results will be reviewed by [CONTACT_137695] (Alexander 
Rodriguez -Palacious, Asst. Professor, Division Gastroente rology).  
 
 
 
 
 
Confidentiality of Specimens and Banking  
Are you storing the specimen (s) for future use for other research projects?  
‚òê  I am not collecting  specimens in this research project   
‚òê  I am not storing specimens in this research project   
‚òí  Yes 
‚òê  No 
If yes, d escribe:  
1. The source of the specimens :  Collecting directly from subjects.      
2. Where the specimens will be st ored:    All specimens will be stored in the Division of 
Gastroenterology in a locked -80C freezer, located on the 5th floor Biomedical Research 
Building (BRB), CWRU.   
3. How long the specimens will be stored :  Samples  will be stored no longer than 10  years.     
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 30 of 48 
4. How the specimens will be labeled :  This study will use a unique study identifier (not 
derived from the participants‚Äô personal identifiers) to code individuals‚Äô data and study 
specimens, and the ID log will be stored separately from the study data.  
Data will be secured by [CONTACT_137696]:  
‚Ä¢ The key code ID log will be kept separately and securely  
‚Ä¢ Data are kept in a locked file cabinet, office, or suite in the Biomedical Research 
Building, 5th floor, CWRU  
‚Ä¢ Electronic data are password -protected stored on UH RedCap.  
      
5. How the specimens will be accessed :   Control access to and use of specimens stored 
under the supervision of the study coordinator.      
6. Who will have access to the specimens :     Only the study investigators will have access 
to the research study samples. The laboratory study team will not ha ve access to the 
master list and no attempt will be made to re -identify the subjects/specimens. The linking 
sheet will be destroyed once the sample collection has been completed. Personnel such as 
regulatory authorities and members of the University Hospit als Cleveland Medical Center 
Institutional Review Board may inspect the subject‚Äôs medical records and the database 
for verification of the accuracy of data.  Medical records and data will be handled by 
[CONTACT_137697], state, an d local laws.        
7. When and how will the specimens be destroyed :  Disposition at the completion of the 
study: All samples will be stored in the Division of Gastroenterology in a locked -80C 
freezer, located on the 5th floor BRB, CWRU. Study participants who request destruction 
of samples will be notified of compliance with such request and all supporting details will 
be maintained for tracking. Samples will be incinerated.     
8. How will the specimens be transported ? (Please note if transporting specimens, a 
Material Transfer Agreement (MTA) is required)  The de -identified, archived data will be 
transmitted to and stored in Division of Gastroenterology of the DDRCC in a locked -
80C freezer, located on the 5th floor BRB , CWRU., Permission to transmit data to the 
DDRCC freezer space will be included in the informed consent.  
      
9. The procedures to release specimens including:  
‚Ä¢ The process to request a release :   we will not be sharing samples  
‚Ä¢ Approvals required for a relea se:     
‚Ä¢ Who can obtain specimens :      
‚Ä¢ The data to be provided with specimens, including if the data will be identifiable to 
others :     
Specime ns will de -identified and sent in batch for analysis and tracked  using unique 
study ID code not derived from participants personal identifiers.   
 
‚òê  For genomic data, please check the box to attest there is no master list and no attempt 
will be made to re -identify the specimens.       
 
Confidentiality of Data  
10. To maintain the confidentiality of the data : 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 31 of 48 
‚òí  I will use a unique study identifier (not derived from the p articipants‚Äô personal 
identif iers) to code individuals‚Äô data  and I will store  this ID log separate from study 
data.  
‚òê  Other   
 
11. How are you storing your electronic data ? 
‚òí  UH Redcap   
‚òê  CWRU Redcap   
‚òê  CWRU‚Äôs SRE ( Secure Research Environment ) 
‚òê  CWRU Box  
‚òê  OnCore  
‚òê  UH Secure Network Drive  
‚òê  CWRU Secure Network Drive  
‚òê  Other  - 
 
12. ‚òí  I acknowledge that paper research data and documents will b e stored in a double - 
      locked secure environment in the following location:   
            Location:  ‚òê  N/A 
Paper research data and documents will be stored in a double -locked secure environment 
in the Biomedical Research Building, 5th Floor, CWRU.  The laboratory study team will 
not have access to the master list and no attempt will be made to re -identify the 
subjects/specimens. The linking sheet will be destroyed once the sample coll ection has 
been completed. Personnel such as regulatory authorities and members of the University 
Hospi[INVESTIGATOR_137645]‚Äôs 
medical records and the database for verification of the accuracy of d ata.  Medical 
records and data will be handled by [CONTACT_137697], state, and 
local laws.  
13. Will data be shared?  
‚òê  N/A 
‚òí  No   
‚òê  Yes  
‚Ä¢ List t he exact data elements that will be shared : 
‚Ä¢ Describe h ow data will be sent:  
 
 
HIPAA Authorization  
If you are going to be accessing PHI (Protected Health Information), indicate how HIPAA  
authorization will be obtained (check all that apply) : 
‚òí  HIPAA authorization is in the consent form  
‚òí  Requesting a full or partial waiver of HIPAA for prescreening  
‚òê  Requesting a full or partial waiver of HIPAA  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156472] access to participants‚Äô PHI and data for identification of 
suitable study participants  (physician notes) , and to facilitate part icipants‚Äô receipt of study 
food (name, telephone number, delivery address)  to evaluate daily QOL and 
gastrointestinal symptoms) and problem solving. (email address ‚Äì questionnaires sent via 
RedCap).  
 
2. If the identifiable information will be used or disclosed by [CONTACT_137698], please state who those individual s/entities are and provide justification for the 
disclosure.   
‚òê  Identifiable information will not be used or disclosed by [CONTACT_137699]   
‚òê  Identifiable information will be used or disclosed to:  
 
3. Describe how long identifiers will be kept for in relation to study length and data 
collection and analysis .  
Research records to be retained for at least 3 years after the completion of the resea rch 
(45 CFR 46) and data will be kept for at least 5 years.  
‚òí  I assure that protected health information collected for purposes of this research study will 
not be reused or disclosed to any other person or entity, except as required by [CONTACT_2371], for 
authorized oversight of the research study, or for other research for which the use of 
disclosure of protected health information for which an authorization or opportunity to 
agree or object is not required by [ADDRESS_156473] the reasonably foreseeable risks such as breach of confidentiality, discomforts, 
hazards, or inconveniences to the research participants related to their participation in the 
research. Include a description of the probability, magnitude, duration , and reversibility 
of the risks. Include  the physical psychological, social, legal, and economic risks .  
 
 
 
5.0 Risks to Research Participants  
5.1 Risks  
Diet 
The intervention in this study poses little risk to participants. The prescribed diets are consistent 
with many dietary recommendations to minimize consumption of ‚Äúprocessed‚Äù foods. 
Nevertheless, it is possible that some participants may feel inconvenience d by [CONTACT_137700], particularly if the study diet contains a higher fiber content to 
that of their usual eating habits (increased flatulence). However, we expect this to be minimal, 
especially in context to the short duration  of the diet intervention. In addition, there is a theoretical 
risk of delaying a change in the patient‚Äôs medication regimen while trying the study diets, however 
we have taken this into consideration in the design of both our inclusion and exclusion crite ria. 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156474]‚Äôs research record private and 
confidential, but absolute confidentiality cannot be guaranteed.  
 
Emotional and psychological risks:  
Participants  may feel uncomfortable about answering questions pertaining to symptoms or diet 
history , or for the online survey, their perceptions on diet and food safety . If participants  do not 
wish to answer a question, they may skip it and go to the next question.  
 
Ethical Considerations  
This study will be conducted in accordance with applicable US Government regulations and 
international standards of Good Clinical Practice.  This protocol, any amendments and any study 
instructions and data collection instruments will be submitted to a properly constituted Ethics 
Committee or Instituti onal Review Board (e.g.  UH IRB), in agreement with local legal 
prescriptions for formal approval of the study conduct.  The decision of the Ethics Committee or 
Institutional Review Board concerning the conduct of the study will be made in writing to the 
investigator and a copy of the decision will be provided to the UH Data Coordinating Center 
(RedCap) before commencement of the study. Continuing review will be required through the UH 
Institutional Review Board or other local reviewing entities at the DHI r ecruiting center.  
 
5.2 SAFETY AND ADVERSE EVENTS  
5.2 Definitions  
5.2.1 Adverse Event  
An adverse event  (AE) is any symptom, sign, illness  or experience that develops or worsens in 
severity during the course of the study.  Intercurrent illnesses or injuries should be regarded as 
adverse events.  Abnormal results of diagnostic procedures are considered to be adverse events if 
the abnormality:  
‚Ä¢ results in study withdrawal  
‚Ä¢ is associated with a serious adverse event  
‚Ä¢ is associated with clinical signs or symptoms  
‚Ä¢ leads to additional treatment or to further diagnostic tests  
‚Ä¢ is considered by [CONTACT_1372]  
 
A preexisti ng condition  is one that is present at the start of the study.  A preexisting condition 
should be recorded as an adverse event if the frequency, intensity, or the character of the condition 
worsens during the study period.  
 
5.2.2 Serious Adverse Event  
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE that 
is:  
‚Ä¢ fatal 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 34 of 48 
‚Ä¢ life-threatening  
‚Ä¢ requires or prolongs hospi[INVESTIGATOR_4408]  
‚Ä¢ results in persistent or significant disability or incapacity  
‚Ä¢ a congenital anomaly or birth defect  
‚Ä¢ an important medical event (not life threatening but may require intervention; for example 
drug overdose, drug abuse, a seizure not resulting in hospi[INVESTIGATOR_059])  
All adverse events that do not meet any of the criteria for  serious should be regarded as non-
serious adverse events .  
 
5.2.3 Expected Adverse Events  
As a short term study of a soy -based diet, there are few expected risks of the diet intervention. 
These include allergic reaction to a component of the food, intolerance of the food other than as 
an allergic reaction, and worsening of Crohn‚Äôs disease manifested as any of the following: 
worsen ed abdominal pain, worsened diarrhea, or other complication such as bowel obstruction 
due to intestinal narrowing or intestinal fistula due to penetrating disease/ulcer. In addition, 
presence of or worsening of pre -existing extraintestinal manifestations o f Crohn‚Äôs disease is 
possible, such as joint pain (arthralgia), mouth sores, skin (e.g., erythema nodosum) or ocular 
manifestations (e.g., uveitis). The Crohn‚Äôs disease related adverse events would not be considered 
to be caused by [CONTACT_137701], but rather as  a consequence of failure of the diet based therapy to sustain 
symptomatic remission. Some exacerbations of Crohn‚Äôs Disease may result in hospi[INVESTIGATOR_65586]/or the need for surgery. In rare circumstances, exacerbations of Crohn‚Äôs disease may be life -
threa tening.  
 
These risks are specified in the protocol and informed consent form.  
 
5.2.3 Recording of Adverse Event (AE)  
At each contact [CONTACT_137702], the primary 
Investigator will seek information on ad verse events by [CONTACT_5147], as appropriate, 
by [CONTACT_137703] a gastroenterologist.  Information on all adverse events will be recorded 
immediately on the AE case report form (CRF). The clinical course of each event will be followed 
until res olution, stabilization, or until it has been determined that the study intervention or 
participation is not the cause.   
Related, treatment -emergent serious and severe adverse events that are still ongoing at the end of 
the study period will be followed up  to determine the final outcome, which may include resolution 
or stable outcome.   
 
5.2.4 Relationship of AE to Study  
The relationship of each adverse event to the study procedures should be characterized by [CONTACT_137704]. The relationship to the study 
intervention will be classified as definitely related, possibly related, not related, or unknown.  For 
reporting purposes, an Adverse Event is considered ‚Äúrelated to participation in the research‚Äù if the 
cause of the event is deemed possibly related or definitely related to the investigational product or 
a procedure that was performed for the purposes of the research.  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 35 of 48 
5.3 Reporting of Serious Adverse Events and Unanticipated Problems  
A Serious Adverse Event or Unanticipated Problem (see definition below) is required to be 
reported to the relying IRB (Case Western Reserve University) within 10 days. If the adverse event 
involved a death and indicates that participants or others are at i ncreased risk of harm the 
investigators are required to submit a report to the relying IRB within 3 days.  
 
*Non-medical Unanticipated Problems  that should be reported to the IRB may include complaint 
of a participant when the complaint indicates unexpected risks or the complaint cannot be resolved 
by [CONTACT_5051], breach of confidentiality, incarceration of a participant, or premature 
completion of the entire study for any reason.  
 
*Serious Adverse Events or Unanticipated Problems  will be rep orted to the relying IRB using 
either a Reportable Event form from the relying IRB, or by [CONTACT_565] a narrative including the 
minimum necessary information listed below.  If not all information is known within the reporting 
timeframe, the investigator should  still complete a Reportable Event form or narrative within the 
timeframe with the information available and inform the relying IRB that a follow -up report will 
be provided when all information is known.  
 
‚Ä¢ Study identifier  
‚Ä¢ Study Center (DHI)  
‚Ä¢ Subject number  
‚Ä¢ A description of the event  
‚Ä¢ Date of onset  ‚Ä¢ Current status  
‚Ä¢ Whether study intervention was discontinued  
‚Ä¢ The reason why the event is classified as 
serious  
‚Ä¢ Investigator assessment of the association 
between the event and study intervention  
 
 
If an event does not meet the definition above of a Serious Adverse Event or Unanticipated 
Problem, a narrative summary of events that occurred should be submitted to the relying IRB at 
the time of Continuing Review, including a rational for why the event( s) was not reportable within 
[ADDRESS_156475], the sponsor, and the relying IRB immediately.  
 
5.3.1 Follow -up SAE report  
If an SAE has not resolved at the time of the initial report and new information arises that changes 
the investigator‚Äôs assessment of the event, a follow -up report including all relevant new or 
reassessed information (e.g., concomitant medication, medical history) should be submitte d to the 
relying IRB. The investigator is responsible for ensuring that all SAEs are followed until either 
resolved or stable.  
 
 
5.3.2 Investigator reporting: notifying the study sponsor  
DHI investigators should report serious adverse events and unanticip ated problems meeting the 3 -
day reporting requirement (as defined in section 5.2) to the DDRCC, DHI UH sponsor by [CONTACT_137705] -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 36 of 48 
and via RedCap. Phone notification should be within 24 hours of the investigator becoming aware 
of the serious adverse event.  
 
A specif ic AE documentation form will be  provided to the investigators . In case of an SAE, this 
should be completed by [CONTACT_099]/gastroenterologist as an initial report, and sent (via fax) to 
the principal investigator. The report must contain a detailed descr iption of the symptoms observed 
and the concomitant treatment administered. Furthermore, the investigator must comment on a 
possible causative relationship between the AE and study diet . Each SAE must be followed until 
it is resolved or can be explained sa tisfactorily. The general procedure for the observation, 
collection and analysis of risks (regulatory affairs) in conformity with the appropriate national 
Drug Law shall apply without qualification. In accordance with drug safety and national 
requirements,  the study PI [INVESTIGATOR_137646] (DSMB) of the study 
and will make sure that the involved persons will obtain adequate information. Also the principal 
investigator [INVESTIGATOR_137647]. Only those SAE will be n otified which might  
affect the safety of the study subjects or the overall conduct of the study.  
 
The following instructions must be heeded:  
In the case of an intolerable SAE, the patient must, at the decision of the investigator, be withdrawn 
from the study, and symptomatic treatment must be administered. The measures taken must be 
recorded on the CRF. In accordance with local legislation, the  investigators will submit copi[INVESTIGATOR_137648] -report to the Regulatory Authorities concerned, if necessary. SAE‚Äôs that do not meet 
the 3 day reporting requirement (i.e., do not involve death or indicate that participants are at 
increased risk) should be reported to the sponsor within 10 days via the data management system 
only. No phone call will be required.  
 
Online survey  (perceptions on diet/food safety on digestive symptoms ): N/A 
 
Address:  
Digestive Health Institute  
University Hospi[INVESTIGATOR_137649], OH   UH Site I nvestigator  
Fabio Cominelli , MD  Phone/fax No:  
[PHONE_3097]  
 
 
 
OR 
Address:  
Dep. of Gastroenterology  
Biomedical Research Bldg., [ADDRESS_156476], LD  Phone/fax No:  
[PHONE_3098]  
 
Fax: 216 -368-0647  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 37 of 48 
For a flow chart outlining SAE reporting to the sponsor, please see Image 1 above . 
  

 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156477] risks to the research 
participants that are currently unforeseeable.   
‚òí  N/A    
3. If applicable, describe the risks to others who are not research participants.   
‚òí  N/A   
4. Describe the availability of medical or psychological resources that research participants 
might need.   
‚òí  N/A   
 
Additional Considerations for Pregnant Women:   
5. Indicate which procedures may have risks to an embryo or fetus should the research 
participant or their partner be or become pregnant.   
‚òí  N/A    
 
‚òê  Each individual providing consent is fully informed regarding the reasonably 
foreseeable impact of the research on the fetus or neonate.  
‚òê  No inducements, monetary or otherwise, will be offered to terminate a pregnancy.  
‚òê  Individuals engaged in the re search will have no part in any decisions as to the timing, 
method, or procedures used to terminate a pregnancy.  
‚òê  Individuals engaged in the research will have no part in determining the viability of a 
neonate.   
 
Provisions to Protect the Privacy I nterests of Research Participan ts 
To protect the research participant‚Äôs privacy interests,  the consent process will occur in a quiet, 
private exam r oom in a private area of the Digestive Health Institute (DHI), UHCMC, or at the 
Dahms Clinical Research Unit at UHCMC .  All additional study visits will also occur in a 
private exam room . This will allow for subjects to feel comfortable about asking and responding 
to questions.   
 
  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 39 of 48 
Potential Benefit to Research Participants  
‚òê  There is potential benefit to research participants.  
1. Describe the potential benefits that individual research participants may experience from 
taking part in the research. Include the probability, magnitude, and duration of the 
potential benefi ts. 
 
‚òí  There is no direct benefit to research participants.  
2. If no direct benefit, state the potential benefit to society or others.   
 
Participants may benefit from participation in this study if the proposed dietary intervention 
reduces their symptoms of CD and the related inflammation. In healthy controls, it is possible that 
the dietary intervention promotes a feeling of individual wel l-being and/or gut health ( e.g., 
improved shape or texture of stool ). If the study diet is demonstrated to be superior to the 
participants usual eating habits , it is anticipated that many patients with CD or healthy individuals 
without CD would elect to fo llow a similar diet.  
 
The leading unanswered question for patients with IBD is what diet to eat. Ultimately, regardless 
of the results, we will provide an answer to the question, ‚ÄúWhat should I eat?‚Äù If the  study  diets is  
demonstrated to be superior, then we can confidently recommend that diet to patients with active 
CD. If the study d iet is found to be superior, the default recommendation will be to follow a 
‚Äúhealthy‚Äù and well -rounded diet such as the soy-based  diet, or t hat originally followed by [CONTACT_137706]. This is a low risk study, so the risks to subjects are reasonable in the context of the 
information to be gain ed.  
 
 
Withdrawal of Research Participants  
‚òê  N/A  
Participants may withdraw from the study at any time.   
Participants may be withdrawn at the discretion of the investigator prior to initiation of diet 
intervention for the following reasons:  
‚Ä¢ Failure to provide stool sample s** 
‚Ä¢ Failure to complete questionnaires  
 
**We have considered that participants may not have a natural bowel movement as anticipated 
during day [ADDRESS_156478] considered this in our inclusion/exclusion criteria. 
Nevertheless, if failure to provide stool sample is a result of absence of natural bowel movement 
at any time during day 5 -7 of a study diet, provision of study meals may be extended and approval 
will be granted by [CONTACT_137707] 7 -day diet.  
Participants will be withdrawn from the study if they experience worsening symptom s requiring 
a change in their Crohn‚Äôs disease treatment.  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156479] been enrolled in the study and completed or partially initiated any part of 
the diet intervention including fasting, and withdraw early from the study should complete an 
end of study visit and provide a stool sample at the time of withdrawal . 
 
If the participant wishes to discontinue the study diet early for reasons not related to worsening 
Crohn‚Äôs Disease (e.g., they don‚Äôt like the diet) , they will be asked to remain in follow -up and 
complete the next in -person visit at the target date of that visit. This will be the end of study visit.  
 
Rescue Therapy [if applicable]  
Participants will remain under the care of their treating gastroenterol ogist while in the study.  If 
their symptoms worsen, participants will contact [CONTACT_137708]‚Äôs disease.  Participants 
whose worsening symptoms require a ch ange in the current treatment for Crohn‚Äôs disease will be 
considered study treatment failures and will be withdrawn from the study. See Withdrawal of 
Research Participants.  
 
 
Unscheduled Visits  
Diet intervention; Unscheduled visits could potentially occur if a participant experiences an 
Adverse Event tha t requires medical evaluation.  Refer to Section 5.2 Safety and Adverse Events in 
protocol.  
 
Alternatives to Participation  
 
‚òí  The alternative is for research subjects not to participate.  
 
Costs to Research Participants  
‚òí  There are no costs to research participan ts or their  insurance companies (there are no clinical 
visits or billable procedures).  
 
 
Research Participant Compensation  
‚òê  There is no compensation or reimbursement for research participants . 
‚òí  There is compensation for research participants.   
‚òê  There will be reimbursement for research participants.   
At completion of study visit 1 and at completion of the end of study visit, participants who 
provide proof of parking will be given a date stamped parking voucher  (3 hours visitor parking) 
to off-set any cost to subjects for participation in this study.   
 
To off -set any cost to participants for participation in this study related to transportation 
expenses, storage, reheating and preparation of study meals, participants will be compensated  a 
total of $[ADDRESS_156480] for their participat ion in this study. Given the short 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page [ADDRESS_156481] consent  to co mplete a W -9 form .   
 
 
Compensation for Research Related Injury  
Describe who will pay for the costs of medical treatment and/or compensation in the event of a 
research related injury : 
‚òê  Funding agency is providing some/all payment for injury  
‚òí  Funding agency is providing no payment for injury  
‚òê  N/A  
All minimal risk research involves a chance of research related injury to the participant. This 
may include the risk of personal injury or illness that is not the result of a pre -existing con dition 
or the normal progression of the participants‚Äô disease. In spi[INVESTIGATOR_31246], a 
participant might develop a reaction or injury from being in this diet study. If such problems 
occur, the University Hospi[INVESTIGATOR_137622] (UHCMC ) principal investigator [INVESTIGATOR_137650]; however, the study sponsor has not 
set aside funds to provide payment for research related injury and UHCMC has no plans to 
provide free care or compensation for lost wages ; any costs for the medical care will be billed to 
the participant and/or the participants insurance company.  
Provisions to Monitor the Data to Ensure the Safety of Research Participants  
1. Describe how often the data will be mon itored for completeness, accuracy and 
adherence to the protocol . 
 
Diet Intervention:  
Data and Safety Monitoring Plan  
To identify and mitigate potential risks to research subjects, we will inquire with 
participants at each contact [CONTACT_137709]. Contact [CONTACT_137710] -person visits. We do not expe ct that 
there will be many as the intervention is normal, healthy food.   
 
As mentioned above, SAE‚Äôs will be reported to the Principal Investigator [INVESTIGATOR_137651], Cleveland, OH  and University Hospi[INVESTIGATOR_137622] . 
Additio nally, we will employ a Data Safety and Monitoring Board (DSMB).  
 
Study Monitoring Plan  
Most of the data to be collected in this study will be collected directly from participants 
using repeat surveys sent via email under our UH RedCap project. For specific aim 1, the 
primary outcome of maintenance of symptomatic remission is derived from par ticipant 
completed surveys. We will monitor for compliance with regulatory documentation and 
for compliance with the study protocol, particularly as it relates to inclusion criteria. We 
will utilize a system whereby [CONTACT_137711], reda cts if needed , and 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 42 of 48 
uploads into RedCap source documents that demonstrate the eligibility of the participants , 
as appropriate.  All documents will be available for remote review for compliance with the 
study protocol. Any findings that demonstrate a protocol  deviation will be reported to the 
UH IRB.  Similar methods will be employed for reviewing the DHI study sites regulatory 
binder.  
The DHI will provide an area where the study regulatory documents can be stored and then 
reviewed by [CONTACT_473]. Data quality monitoring will be implemented after the 
second patient is enrolled at the DHI. Eligibility criteria and consent process will be 
monitored for all participants. If deemed necessary, on site monitoring will be employed.  
Clinical data and baseline characteristics of the participants and follow -up data on adverse 
events and physician derived components of the CDAI will be collected by [CONTACT_137712] . All data analysis for secondary outcomes for 
specific aim 1 (changes to  fecal bacteria composition and butyrate) will be performed 
blinded by  [CONTACT_137695].  
Auditing and Inspecting  
The principal investigator [INVESTIGATOR_137652] -related monitoring, audits, and inspections by 
[CONTACT_1201], the sponsor, government reg ulatory bodies, and University compliance and 
quality assurance groups of all study related documents (e.g. source documents, regulatory 
documents, data collection instruments, study data etc.).  The investigator will ensure the 
capability for inspections of applicable study -related facilities.  
Participation as an investigator in this study implies acceptance of potential inspection by 
[CONTACT_137713].  
 
2. Indicate if there wi ll be a Data and Safety Monitoring Board or Committee:  
‚òê  There will not be a formal Data and Safety Monitoring Board/Committee.  
 
‚òí  There will be a formal Data and Safety Monitoring Board/Committee.   
Data Safety Monitoring Board  
We will convene a DSMB prior to the initiation of the study. The DSMB memb ership 
will include 3  total members consisting of: 1 statistician, 2  experienced clinical 
investigator s with knowledge of Crohn‚Äôs disease . The DSMB will have full authority to 
recommend susp ending the study at any time if concerns arise about the safety of the 
study. Formal meetings of the DSMB will be planned to occur after half of patients are 
enrolled and at the conclusion of the trial.  
 
DSMB meetings will follow the standard format of an  open session including the DSMB 
members and the investigators, followed by a closed session of the DSMB at which 
unblinded data can be reviewed, followed by [CONTACT_137714]. The 
DSMB will render a decision to continue the study as is, con tinue the study with 
modifications, suspend the study until modifications can be implemented, or to 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 43 of 48 
permanently suspend the trial. The study team will provide support to the DSMB to 
generate meeting minutes.  The meeting minutes will be provided to the UH IRB.  
 
SAE reports will be sent as they occur to the chair of the DSMB for review.  
  
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 44 of 48 
 
 
Drugs or Devices  
‚òí  This is not a drug or device study . The protocol is considered non -therapeutic (non -therapeutic 
is defined as research not intended to diagnose, prevent, cure, mitigate, treat, etc. a disease or 
condition)  by [CONTACT_1622] . ‚Äì  
OR 
‚òê This is a drug or device study.  The protocol is considered therapeutic (research intended to 
diagnose, prevent, cure, mitigate, treat a disease or condition)  by [CONTACT_1622].   
 
1. Is there an active IND (Investigational New Drug) or IDE (Investigational Device Exemption) 
for the proposed clinical research study?  
‚òê Yes, provide an official letter of support or proof of approval which identifies the 
IND/IDE holder and IND/IDE number.   
‚òí  No,  
 
2. Is the drug IND exempt OR is the device (and its use) a non -significant risk device for the 
proposed study design?  
‚òê  Yes 
‚òê No  
‚òí  N/A 
 
 
Additional Information  
Community -Based Participatory Research  
‚òí  This is not a community -based participatory research project   
‚òê  This is a community -based participatory research project  
 
Note: Community based research is research that is conducted as an equal partnership between 
academic investigators and members of a community. In Community Based Participatory 
Research (CBPR) protects, the community participates fully in all aspects of the research 
process .   
 
International information  
‚òí  This is not an international study   
 
MULTI -SITE RESEARCH (when UH or CWRU is the IRB of Record ) 
Does this project have multiple sites ? 
‚òê  Yes 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 45 of 48 
‚òí  No  
 
 
Non-Local Site Information  for Multi -Site Studies  
If this is a multi -site study where you are the lead investigator , list the following information for 
each relying site : 
1. Name [CONTACT_50854] :  
2. PI [INVESTIGATOR_137653] :  
3. Name [CONTACT_137719] :  
4. Phone number of IRB contact :  
5. Email address of IRB contact :  
 
[CONTACT_51584]-Local Recruitment Methods for Multi -Site Studies  
If this is a multi -site study and research participants will be recruited by [CONTACT_137715]  (e.g. call centers, national advertisements) describe those methods. 
Local recruitment methods are described above .  
1.   Describe when, where, and how potential research participants will be recruited .  
 
1. Describe the methods that will be used to identify potential research participants .  
 
2. Describe the materials that will be used to recruit research participants .  
 
Mult i-Site Research Communication Plan (when you are the lead investigator ) 
If this is a multi -site study where you are the lead investigator , describe the processes to e nsure 
communication among sites including : 
‚òê  All sites will have the most current version of the protocol, consent document, and HIPAA 
authorization       
‚òê  All required approvals (initial, continuing review and modifications) have been obtained at 
each site (including approval by [CONTACT_779]‚Äôs IRB of record)      
‚òê  All modifications have been communicated to sites, and approved (including approval of the 
site‚Äôs IRB of record) before the modification is implemented      
‚òê  All engaged participating sites will safeguard data, including secure transmission of data, as 
required by [CONTACT_28584]  
‚òê  All engaged participating sites will safeguard data, including secure transmission of data, as 
required by [CONTACT_28584]       
‚òê  All local site investigators conduct the study in accordance with applicable federal 
regulations and l ocal laws       
‚òê  All non -compliance with the study protocol or applicable requirements will be reported in 
accordance with local policy       
If thi s is a multi -site study where you are the lead investigator, describe the method for 
communicating to engaged participant sites  the following :  
1.   Problems :      
2.   Interim results :      
3.   The closure of the study :      
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 46 of 48 
 
 
 
References     
  
Please reference the Investigator Manual for local institutional requirements.  
 
 
 
1. Thia, K.  et al.  Short CDAI: development and validation of a shortened and simplified Crohn's 
disease activity index. Inflamm Bowel Dis  17, 105-111 (2011).  
 
2. Best, W.R., Becktel, J.M., Singleton, J.W. & Kern, F., Jr. Development of a Crohn's disease activity 
index. National Cooperative Crohn's Disease Study. Gastroenterology  70, 439-444 (1976).  
 
3. Harvey, R.F. & Bradshaw, J.M. A simple index of Crohn's -disease activity. Lancet  1, 514 (1980).  
 
4. Cosnes, J., Gower -Rousseau, C., Seksik, P. & Cortot, A. Epi[INVESTIGATOR_137654]. Gastroenterology  140, 1785 -1794 (2011).  
 
5. Peyrin -Biroulet, L., Loftus, E.V., Jr., Colombel, J.F. & Sandborn, W.J. The  natural history of adult 
Crohn's disease in population -based cohorts. Am J Gastroenterol  105, 289-297 (2010).  
 
6. Dignass, A.  et al.  The second European evidence -based Consensus on the diagnosis and 
management of Crohn's disease: Current management. J Cro hns Colitis  4, 28-62 (2010).  
 
7. Sandborn, W.J., Feagan, B.G. & Lichtenstein, G.R. Medical management of mild to moderate 
Crohn's disease: evidence -based treatment algorithms for induction and maintenance of 
remission. Aliment Pharmacol Ther  26, 987-1003 ( 2007).  
 
8. Colombel, J.F.  et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. N. 
Engl. J. Med.  362, 1383 -1395 (2010).  
 
9. Hanauer, S.B.  et al.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. 
Lancet  359, 1541 -1549 (2002).  
 
10. Colombel, J.F.  et al.  Adalimumab for maintenance of clinical response and remission in patients 
with Crohn's disease: the CHARM trial. Gastroenterology  132, 52-65 (2007).  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 47 of 48 
11. Lewis, J.D.  et al.  Timing of myelosuppression during thiopurine therapy for inflammatory bowel 
disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol  7, 1195 -
1201; quiz 1141 -1192 (2009).  
 
12. Present, D.H., Meltzer, S.J., Krumholz, M.P., Wolke, A. & Korelitz, B.I. 6 -Mercaptopurine in the 
management of inflammatory bowel disease: short - and long -term toxicity. Ann Intern Med  111, 
641-649 (1989).  
 
13. Siegel, C.A., Marden, S.M., P ersing, S.M., Larson, R.J. & Sands, B.E. Risk of lymphoma associated 
with combination anti -tumor necrosis factor and immunomodulator therapy for the treatment 
of Crohn's disease: a meta -analysis. Clin Gastroenterol Hepatol  7, 874-881 (2009).  
 
14. Beaugerie , L. et al.  Lymphoproliferative disorders in patients receiving thiopurines for 
inflammatory bowel disease: a prospective observational cohort study. Lancet  374, 1617 -1625 
(2009).  
 
15. Busch, K.  et al.  Sick leave and disability pension in inflammatory bowe l disease: a systematic 
review. J Crohns Colitis  8, 1362 -1377 (2014).  
 
16. van der Have, M.  et al.  Self-reported disability in patients with inflammatory bowel disease 
largely determined by [CONTACT_137716]. Inflamm Bowel Dis  21, 369-377 
(2015).  
 
17. Lichtenstein, G.R., Yan, S.K., Bala, M. & Hanauer, S. Remission in patients with Crohn's disease is 
associated with improvement in employment and quality of life and a decrease in 
hospi[INVESTIGATOR_137655]. American Journal of Gastr oenterology  99, 91-96 (2004).  
 
18. Kappelman, M.D.  et al.  Evaluation of the patient -reported outcomes measurement information 
system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol 
Hepatol  12, 1315 -1323 e1312 (2014).  
 
19. Graff, L.A.  et al.  The relationship of inflammatory bowel disease type and activity to 
psychological functioning and quality of life. Clin Gastroenterol Hepatol  4, 1491 -1501 (2006).  
 
20. Bewtra, M., Kaiser, L.M., TenHave, T. & Lewis, J.D. Crohn's disease and ulcerative colitis are 
associated with elevated standardized mortality ratios: a meta -analysis. Inflamm Bowel Dis  19, 
599-613 (2013).  
 
21. Johnson, F.R.  et al.  Crohn's disease patients' risk -benefit preferences: serious adverse event risks 
versus treat ment efficacy. Gastroenterology  133, 769-779 (2007).  
 
 HRP -503BIO  TEMPLATE: Biomedical Protocol  
Approved:  7/9/2019  Prior Version:   
 
  Page 48 of 48 
22. Sands, B., Siegel, C., Ozdemir, S., Hass, S. & Miller, D. Gastroenterologists' tolerance for Crohn's 
disease treatment risks. American Journal of Gastroenterology  102, S492 -S492 (2007).  
 
23. Peyrin -Biroulet, L.  et al.  Clinical disease activity, C -reactive protein normalisation and mucosal 
healing in Crohn's disease in the SONIC trial. Gut 63, 88-95 (2014).  
 
24. Bitzer, Z.T.  et al.  Soy protein concentrate mitigates markers of colonic inflammation and loss of 
gut barrier function in vitro and in vivo. J Nutr Biochem  40, 201-208 (2017).  
 
25. Gibson, G.R. & Roberfroid, M.B. Dietary modulation of the human colonic micro biota: 
introducing the concept of prebiotics. J Nutr  125, 1401 -1412 (1995).  
 
26. Bindels, L.B., Walter, J. & Ramer -Tait, A.E. Resistant starches for the management of metabolic 
diseases. Curr Opin Clin Nutr Metab Care  18, 559-565 (2015).  
 
27. Kang, M., Rag an, B.G. & Park, J.H. Issues in outcomes research: an overview of randomization 
techniques for clinical trials. J Athl Train  43, 215-221 (2008).  
 
28. Menghini, P.  et al.  Neutralization of IL -1Œ± ameliorates Crohn's disease -like ileitis by [CONTACT_137717]. Proc Natl Acad Sci U S A  (2019).  
 
29. Corridoni, D.  et al.  Dysregulated NOD2 predisposes SAMP1/YitFc mice to chronic intestinal 
inflammation. Proc Natl Acad Sci U S A  110, [ZIP_CODE] -[ZIP_CODE] (2013).  
 
30. Basson, A.  et al.  Artificial mi crobiome heterogeneity spurs six practical action themes and 
examples to increase study power -driven reproducibility. Sci Rep  10, Article number: 5039 
(2019).  
 
31. Corridoni, D.  et al.  Genetic deletion of the bacterial sensor NOD2 improves murine Crohn's 
disease -like ileitis independent of functional dysbiosis. Mucosal Immunol  10, 971-982 (2017).  
 
32. Janyasupab, M.  et al.  Detection of Lysyl Oxidase -Like 2 (LOXL2), a Biomarker of Metastasis from 
Breast Cancers Using Human Blood Samples. Recent Pat Biomark  5, 93-100 (2015).  
 
33. Wan, T.  et al.  A Radio -genomics Approach for Identifying High Risk Estrogen Receptor -positive 
Breast Cancers on DCE -MRI: Preliminary Results in Predicting OncotypeDX Risk Scores. Sci Rep  6, 
[ZIP_CODE] (2016).  
 
 